Akero Therapeutics (AKRO) reported a Q1 net loss Monday of $0.90 per diluted share, unchanged from a year earlier.
Analysts polled by FactSet expected $1.02 loss.
The company did not report any revenue for the quarter ended March 31.
As of March 31, the company said it had $1.13 billion in cash, cash equivalents, and short- and long-term marketable securities, expected to fund operations into 2028.
The company's shares were up 4.1% in recent premarket activity Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.